Side Effect Management
Caregivers were also more likely to have greater care-related burden when patients reported requiring help with fewer IADLs than did the caregiver.
Telotristat represents a new treatment option that may decrease diarrhea incidence with a relatively safe side effect profile.
Researchers enrolled 17,202 individuals, half of whom were cancer survivors and half of whom were healthy controls, to compare opioid prescription rates between the 2 groups.
The FDA expanded the indications of ibrutinib to include the treatment of adult patients with cGVHD who have failed at least one prior therapy.
Mixed data highlight the need for researchers to conduct studies to understand the clinical, rather than just theoretical, risks of HDIs and DDIs.
Adverse events observed in sarcoma survivors highlights the increased need for new, safe treatments, as complications may not be seen until years after the completion of therapy.
Cancer Therapy Advisor asked Dr Kumar to discuss his team's investigation into a dexamethasone dosing schedule for reducing the rates of peripheral neuropathy.
Tamoxifen- and Placebo-induced Symptoms Yield Similar Adherence Rates to Breast Cancer Prophylactics
The treatment arms had similar rates of non-adherence, suggesting that patients may misattribute naturally occurring symptoms to preventative therapy.
Ginger (Zingiber officinale) does not improve chemotherapy-induced nausea and vomiting among patients with cancer.
Consuming Korean red ginseng was reported to improve cancer-related fatigue among Korean patients with colorectal cancer (CRC) treated with FOLFOX.
Drug Info Database
More from Oncology Nurse Advisor
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Checkpoint Inhibition in Multiple Myeloma After Pembrolizumab-related Clinical Trial Deaths
- NSCLC: Genetic Mutations May Determine Likelihood of Metastasis at Diagnosis
- Pembrolizumab Demonstrates Safety and Efficacy in Small-cell Lung Cancer
- FDA Grants Priority Review to Brentuximab sBLA for Cutaneous T Cell Lymphoma
- CAR T Cell Therapy for Acute Lymphoblastic Leukemia: An Evolutionary Perspective